G.R. No. 50720 - Mata vs. Bayona

Case Summary (G.R. No. 50720)

Factual Background

The controversy concerned mutual claims to the trademarks BAYER and BAYER CROSS IN CIRCLE as used in the Philippines. SPI marketed medicines in the Philippines under those marks, notably Bayer Aspirin, Aspirin for Children, and Cafiaspirina, displaying the marks on bottles, strips and boxes. FBA, through AMATCO, distributed industrial and agricultural chemicals including “Folidol,” which bore a replica of the BAYER CROSS IN CIRCLE mark on containers and labels. Each principal party sought exclusive authority over the marks in the Philippine market for different classes of goods.

Corporate and Trademark History

The mark BAYER originated as the surname of Friedrich Bayer and was used by Farbenfabriken vorm. Friedr. Bayer & Co. (FFB), a German chemical concern that later became part of I.G. Farbenindustrie. The BAYER CROSS IN CIRCLE was registered in Germany in 1904 and re-registered in 1929. FFB and its successors registered the mark in several foreign jurisdictions. A United States subsidiary and subsequent transactions led to U.S. registrations and, after seizure under the Trading with the Enemy Act during World War I, sale of U.S. assets to Sterling Drug, Inc., whose Philippine affiliate later secured Philippine registrations for the marks.

Prior Agreements and Litigation Affecting Rights

Contracts executed April 9, 1923, and amended November 15, 1926, allocated territorial and product rights among FFB, Winthrop Chemical Co., Inc., and Bayer New York; these agreements contained provisions relevant to sales in the Philippines. United States antitrust proceedings culminated in consent decrees of September 5, 1941, that declared the 1923 and 1926 contracts unlawful under U.S. antitrust law but expressly preserved rights or title in the name Bayer and the Bayer Cross mark.

Philippine Registrations and Use

The Bayer marks were registered in the Philippines in 1939 by The Bayer Co., Inc., later assigned to SPI and recorded in 1947. Under the postwar statutory scheme, SPI obtained new Philippine certificates on June 18, 1948 (Nos. 1260-S and 1262-S), but those registrations covered medicines only. FBA applied in 1959 for registration in the Philippines for animal and plant destroying agents; after examination and correspondence FBA received a supplemental registration on February 25, 1960 (SR-304).

Procedural History

SPI filed suit for trademark infringement and unfair competition seeking cancellation of FBA’s supplemental registration and exclusion of FBA from using the marks in the Philippines beyond medicines. FBA counterclaimed for cancellation of SPI’s principal-register certificates. The trial court dismissed both complaint and counterclaim but declared that SPI had the right to use the BAYER marks for medicines while defendants could use them for chemicals and insecticides, and ordered defendants to add a distinctive word or words to their mark indicating German origin. Both parties appealed.

Trial Court’s Findings and Order

The trial court framed a practical solution of market division to avoid monopoly and consumer confusion. The court found historical evidence that Bayer Germany had first introduced Bayer medical products into the Philippine market and that the public associated the Bayer mark with German manufacture. It sustained SPI’s use for medicines, allowed defendants’ continued use for non-medicinal chemicals, and required defendants to add identifying words indicating that their products came from Germany.

Issues Presented on Appeal

The appeals raised whether SPI could enjoin FBA and AMATCO from using the Bayer marks in the Philippines for chemicals and insecticides; whether FBA could cancel SPI’s registrations for medicines; whether Philippine registrations abroad or in the United States afforded territorial rights in the Philippines; and whether use, registration, or equitable considerations like clean hands and laches affected the parties’ rights.

Supreme Court’s Disposition

The Supreme Court affirmed the trial court’s judgment. It sustained SPI’s right to use the BAYER trademarks for medicines and allowed defendants to continue using the same trademarks for chemicals and insecticides, subject to the requirement that defendants add a distinctive word or words indicating that their products came from Germany. The Court dismissed both parties’ broader exclusionary claims and denied costs.

Legal Basis: Use Requirement and Scope of Registration

The Court reiterated the foundational rule that ownership of a trademark is acquired by actual use in commerce, as embodied in Section 2-A of the Trademark Law (as amended by Republic Act 638). Registration is a declaratory administrative act and does not of itself perfect rights beyond the goods actually used and stated. The Court emphasized Section 11 and Section 7 requirements that certificates must specify the particular goods for which registration is claimed and that the Director must examine applications to ensure conformity with the statute’s use prerequisite. Because SPI had used the marks in the Philippines only on medicines, its certificates were limited to medicines and did not, by their terms, cover chemicals or insecticides.

Territoriality of Trademark Rights

The Court applied the territoriality principle in trademark law. It held that foreign registrations, including a 1927 United States registration relied on by plaintiff, conferred no automatic protection in the Philippines. The proper inquiry focused on the trade and goodwill established within the Philippine territory.

Confusion of Origin Rule and Comparative Analysis with Ang v. Teodoro

The Court analyzed the scope of protection when goods are noncompeting by reference to the confusion of origin rule and the Court’s prior decision in Ang vs. Teodoro. Two species of confusion were noted: confusion of goods and confusion of business (origin). Although noncompeting goods may still give rise to unfair competition when use of an identical mark is likely to cause confusion of origin, the Court found the present facts distinguishable from Ang vs. Teodoro. The Court accepted the trial court’s factual findings that (1) the German predecessor of defendants first introduced Bayer medicines into the Philippines; (2) the public associated the Bayer mark with German manufacture; and (3) SPI marketed its products in a manner that fostered that association. The Court concluded that SPI had in part “ridden” on the reputation that Bayer Germany had already established and could not now claim an absolute exclusionary right against defendants’ use on different goods.

Equitable Considerations and Clean Hands

The Court invoked equitable principles. It held that SPI could not claim exclusive relief in equity while it had encouraged public belief that its medicines originated in Germany and thus profited from the reputation of the German predecessor. The doctrine that “he who comes into equity must come with clean hands” weighed against an expansive protective remedy for SPI. The Court found no showing of injury to SPI that would justify cancellation of defendants’ registrations or broader

Case Syllabus (G.R. No. 50720)

Parties and Procedural Posture

Sterling Products International, Inc. filed suit for trademark infringement and unfair competition and appealed from the trial court's judgment in part.
Farbenfabriken Bayer Aktiengesellschaft and Allied Manufacturing & Trading Co., Inc. answered, counterclaimed for cancellation of SPI's registrations, and appealed from the portions of the trial court's judgment favorable to SPI.
The trial court dismissed both the complaint and the counterclaim but adjudicated that SPI may use the BAYER marks for medicines while defendants may use the same marks for chemicals and insecticides, and ordered defendants to add a distinguishing word or words indicating German origin.
Both parties sought review of the divisions of market rights and the cancellation and registration determinations made by the trial court.

Key Factual Allegations

SPI marketed Bayer Aspirin, Aspirin for Children, and Cafiaspirina in the Philippines and used the BAYER and BAYER CROSS IN CIRCLE marks on those medicines.
FBA, through AMATCO, distributed industrial and agricultural products including Folidol, which bore a replica of the BAYER CROSS IN CIRCLE on its containers.
The mark BAYER CROSS IN CIRCLE was registered in Germany in 1904 and later abroad, and the surname BAYER originated with Friedrich Bayer who established the business in 1863.
After corporate reorganizations and transfers in the United States, assets and rights relating to the BAYER marks were sold to Sterling interests following seizure under the Trading with the Enemy Act and later transactions.
SPI's Philippine registrations for BAYER and BAYER CROSS IN CIRCLE trace to The Bayer Co., Inc.'s 1939 registrations and to SPI's recorded assignment in 1942, with Philippine reissuance in 1948 limited to medicines.
FBA applied for registration of BAYER CROSS IN CIRCLE for animal and plant destroying agents in 1959 and obtained supplemental registration in 1960.
Evidence in the record showed historical distribution and advertising that associated the BAYER name and cross with German manufacture and high quality in the Philippines.

Statutory Framework

Act 666 governed trademarks before its repeal and provided the original registration regime referenced in the record.
Republic Act 166 succeeded Act 666 as the Trademark Law that required particularity in goods described in a registration certificate.
Republic Act 638 inserted Section 2-A into the Trademark Law to define acquisition of ownership by actual use, and the Court relied on Section 2-A for the principle that actual use in commerce is prerequisite to exclusive ownership.
The Court applied Section 7 and Section 11 of the Trademark Law as to examination of applications and the requirement that a certificate state the particular goods and the date of first use.
Section 9-A of the Trademark Law was invoked in the discussion of cancellation for nonuse.

Issues Presented

Whether SPI's Philippine registrations and use of BAYER marks for medicines afford it exclusive rights to prevent FBA from using the same marks on chemicals and insecticides in the Philippines.
Whether FBA may cancel SPI's principal registrations for BAYER marks for medicines and obtain principal-registration rights for the same marks.
Whether the trial court erred in ordering FBA to add a distinctive word or words indicating German origin to its mark.

Contentions of Parties

SPI contended that its registrations and prior U.S. registrations conferred exclusive rights to the BAYER marks and that defendants' registration and use created confusion of origin and unfair competition.
FBA contended that its German predecessors first introduced B